Adaptive Viral Load Monitoring Frequency to Facilitate Differentiated Care: A Modeling Study From Rakai, Uganda.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
14 08 2020
Historique:
received: 18 04 2019
accepted: 11 09 2019
pubmed: 19 9 2019
medline: 28 4 2021
entrez: 19 9 2019
Statut: ppublish

Résumé

After scale-up of antiretroviral therapy (ART), routine annual viral load monitoring has been adopted by most countries, but reduced frequency of viral load monitoring may offer cost savings in resource-limited settings. We investigated if viral load monitoring frequency could be reduced while maintaining detection of treatment failure. The Rakai Health Sciences Program performed routine, biannual viral load monitoring on 2489 people living with human immunodeficiency virus (age ≥15 years). On the basis of these data, we built a 2-stage simulation model to compare different viral load monitoring schemes. We fit Weibull regression models for time to viral load >1000 copies/mL (treatment failure), and simulated data for 10 000 individuals over 5 years to compare 5 monitoring schemes to the current viral load testing every 6 months and every 12 months. Among 7 monitoring schemes tested, monitoring every 6 months for all subjects had the fewest months of undetected failure but also had the highest number of viral load tests. Adaptive schemes using previous viral load measurements to inform future monitoring significantly decreased the number of viral load tests without markedly increasing the number of months of undetected failure. The best adaptive monitoring scheme resulted in a 67% reduction in viral load measurements, while increasing the months of undetected failure by <20%. Adaptive viral load monitoring based on previous viral load measurements may be optimal for maintaining patient care while reducing costs, allowing more patients to be treated and monitored. Future empirical studies to evaluate differentiated monitoring are warranted.

Sections du résumé

BACKGROUND
After scale-up of antiretroviral therapy (ART), routine annual viral load monitoring has been adopted by most countries, but reduced frequency of viral load monitoring may offer cost savings in resource-limited settings. We investigated if viral load monitoring frequency could be reduced while maintaining detection of treatment failure.
METHODS
The Rakai Health Sciences Program performed routine, biannual viral load monitoring on 2489 people living with human immunodeficiency virus (age ≥15 years). On the basis of these data, we built a 2-stage simulation model to compare different viral load monitoring schemes. We fit Weibull regression models for time to viral load >1000 copies/mL (treatment failure), and simulated data for 10 000 individuals over 5 years to compare 5 monitoring schemes to the current viral load testing every 6 months and every 12 months.
RESULTS
Among 7 monitoring schemes tested, monitoring every 6 months for all subjects had the fewest months of undetected failure but also had the highest number of viral load tests. Adaptive schemes using previous viral load measurements to inform future monitoring significantly decreased the number of viral load tests without markedly increasing the number of months of undetected failure. The best adaptive monitoring scheme resulted in a 67% reduction in viral load measurements, while increasing the months of undetected failure by <20%.
CONCLUSIONS
Adaptive viral load monitoring based on previous viral load measurements may be optimal for maintaining patient care while reducing costs, allowing more patients to be treated and monitored. Future empirical studies to evaluate differentiated monitoring are warranted.

Identifiants

pubmed: 31532827
pii: 5571546
doi: 10.1093/cid/ciz880
pmc: PMC7428397
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1017-1021

Subventions

Organisme : FIC NIH HHS
ID : D43 TW010557
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : PEPFAR
Pays : United States

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

Clin Infect Dis. 2014 Feb;58(3):407-12
pubmed: 24218101
Trop Med Int Health. 2015 Nov;20(11):1462-1472
pubmed: 26146863
AIDS. 2009 Mar 27;23(6):697-700
pubmed: 19209067
AIDS. 2013 Jun 1;27(9):1483-92
pubmed: 23462219
PLoS Med. 2013 Aug;10(8):e1001494
pubmed: 23940461
AIDS. 2011 Jun 1;25(9):1143-51
pubmed: 21505319
J Int AIDS Soc. 2016 Dec 01;19(1):21484
pubmed: 27914186
J Clin Microbiol. 2014 Sep;52(9):3377-83
pubmed: 25031444
Clin Infect Dis. 2007 Jan 1;44(1):128-34
pubmed: 17143828
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):22024
pubmed: 28770588
J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):74-8
pubmed: 23774877
Lancet HIV. 2018 Jan;5(1):e8-e9
pubmed: 29290227
Trop Med Int Health. 2012 Sep;17(9):1152-5
pubmed: 22487689

Auteurs

Victor Ssempijja (V)

Clinical Monitoring Research Program Directorate, Clinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, USA.

Martha Nason (M)

Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Gertrude Nakigozi (G)

Rakai Health Sciences Program, Kalisizo, Uganda.

Anthony Ndyanabo (A)

Rakai Health Sciences Program, Kalisizo, Uganda.

Ron Gray (R)

Rakai Health Sciences Program, Kalisizo, Uganda.
Bloomberg School of Public Health, Baltimore, Maryland, USA.

Maria Wawer (M)

Rakai Health Sciences Program, Kalisizo, Uganda.
Bloomberg School of Public Health, Baltimore, Maryland, USA.

Larry W Chang (LW)

Rakai Health Sciences Program, Kalisizo, Uganda.
Bloomberg School of Public Health, Baltimore, Maryland, USA.
School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

Erin Gabriel (E)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Thomas C Quinn (TC)

School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Division of Intramural Research, NIAID, NIH, Bethesda, Maryland, USA.

David Serwadda (D)

Rakai Health Sciences Program, Kalisizo, Uganda.
Makerere University, School of Public Health, Kampala, Uganda.

Steven J Reynolds (SJ)

Rakai Health Sciences Program, Kalisizo, Uganda.
School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Division of Intramural Research, NIAID, NIH, Bethesda, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH